Monitoring Diabetic Nephropathy by Circulating Gangliosides

Journal of Immunoassay and Immunochemistry

Volumn 37, Issue 1, 2016, Pages 68-79

  Ene, Corina Daniela ^a   Penescu, Mircea ^a   Anghel, Amalia ^b   Neagu, Monica ^c   Budu, Vlad ^d   Nicolae, Ilinca ^c  

^a Clin Nephrol Hosp Dr Carol Davila   (Romania)

^b Skinmed Clinic   (Romania)

^c VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^d Institute of Phonoaudiology and Functional ENT Surgery Prof Dr D Hociota   (Romania)

Author keywords

diabetes; diabetic nephropathy; glomerulonephritis; sialic acid ganglioside

Indexed keywords

CREATININE; GANGLIOSIDE; GLUCOSE; HEMOGLOBIN A1C; SIALIC ACID; UREA; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; N ACETYLNEURAMINIC ACID;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; UREA BLOOD LEVEL; AGED; ALBUMINURIA; BLOOD; CASE CONTROL STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; METABOLISM; MIDDLE AGED; PHYSIOLOGIC MONITORING; PROSPECTIVE STUDY;

AGED; ALBUMINURIA; BIOMARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GANGLIOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; N-ACETYLNEURAMINIC ACID; PROSPECTIVE STUDIES; UREA;

EID: 84954288596     PISSN: 15321819     EISSN: 15324230     Source Type: Journal    
DOI: 10.1080/15321819.2015.1050107     Document Type: Article

References (31)

1. Nicolae, I.; Caragheorgheopol, A.; Schipor, S.; Nicolae, C.; Paun, D.; Coman, O.; Benea, V. Gangliosides and Sex Hormones in Human Melanoma. Acta Endo. 2011, 7, 337-344.
2. Ene (Nicolae), C-D.; Nicolae I., Gangliosides and Antigangliosides in Malignant Melanoma. In Melanoma - Current Clinical Management and Future Therapeutics, Murph, M. (Ed.); Intech, 2015, Ch. 14.
3. Nicolae, C.; Nicolae, I. Heterogeneity of gangliosides in melanocytic tumors. Acta Endo. 2012, 8, 17-26.
4. Nicolae, C.D.; Nicolae, I. Antibodies against GM1 Gangliosides Associated with Metastatic Melanoma. Acta Dermatovenerologica Croatica. 2013, 21, 86-90.
5. Ruh, H.; Sandhoff, R.; Meyer, B.; Gretz, N.; Hopf, C. Quantitative Characterization of Tissue Globotetraosylceramides in a Rat Model of Polycystic Kidney Disease by PrimaDrop Sample Preparation and Indirect High-Performance Thin Layer Chromatography-Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight-Mass Spectrometry with Automated Data Acquisition. Anal. Chem. 2013, 85, 6233-6240.
6. Natoli, T. A.; Smith, L. A.; Rogers, K. A.; Wang, B.; Komarnitsky, S.; Budman, Y.; Belenky, A.; Bukanov, N.O.; Dackowski, W.R.; Husson, H.; Russo, R.J.; Shayman, J.A.; Ledbetter, S.R.; Leonard, J.P.; Ibraghimov-Beskrovnaya, O. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nature Med. 2010, 16, 788-792.
7. Cowart, L. A. Sphingo. and Metab. Dis. Vol. 721. Springer Science+Business Media: New York, 2011.
8. Sun, Y.; Zhou, H.; Yang, B. X. Drug discovery for polycystic kidney disease. Acta. Pharma. Sinica., 2011, 32, 805-816.
9. Ariga, T.; McDonald, M. P.; Robert, K. Y. Thematic Review Series: Sphingolipids. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease - a review. J. Lipid Res. 2008, 49, 1157-1175.
10. Novak, A.; Mužinić, N. R.; Čulić, V. Č.; Božić, J.; Kurir, T. T.; Ferhatović, L., Puljak, L.; Markotić, A. Renal distribution of ganglioside GM3 in rat models of types 1 and 2 diabetes. J. Physio. Biochem. 2013, 69, 727-735.
11. Masson, E.; Troncy, L.; Ruggiero, D.; Wiernsperger, N.; Lagarde, M.; El Bawab, S. a-Series Gangliosides Mediate the Effects of Advanced Glycation End Products on Pericyte and Mesangial Cell Proliferation A Common Mediator for Retinal and Renal Microangiopathy? Diabetes 2005, 54, 220-227.
12. Tsuboi, N.; Utsunomiya, Y.; Kawamura, T.; Kawano, T.; Hosoya, T.; Ohno, T.; Yamada, H. Ganglioside as an endogenous growth suppressor for glomerular mesangial cells. Kidney Int. 2001, 60, 1378-1385.
13. Rauvala, H. Isolation and partial characterization of human kidney gangliosides. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism, 1976, 424, 284-295.
14. Holthofer, H., Reivinen, J., & Miettinen, A. Nephron segment and cell-type specific expression of gangliosides in the developing and adult kidney. Kidney Int. 1994, 45, 123-130.
15. Aguilar, R. P.; Genta, S.; Sánchez, S. Renal gangliosides are involved in lead intoxication. J. Appl. Toxicol. 2008, 28, 122-131.
16. Sunder-Plassmann, G. Renal manifestations of Fabry disease. In Fabry disease, Mehta A.; Beck M; Sunder-Plassmann G (Eds.), Oxford, UK: PharmaGenesis, 2006, Ch. 21.
17. Liebau, M. C.; Braun, F.; Höpker, K.; Weitbrecht, C.; Bartels, V.; Müller, R. U.; Brodesser, S.; Saleem, M.A.; Benzing, T.; Schermer, B.; Cybulla, M.; Kurschat, C. E. Dysregulated autophagy contributes to podocyte damage in Fabry's disease. PloS One 2013, 8, e63506.
18. Hoon, D. S.; Okun, E.; Neuwirth, H.; Morton, D. L.; Irie, R. F. Aberrant expression of gangliosides in human renal cell carcinomas. J. Urol. 1993, 150, 2013-2018.
19. Tringali, C.; Lupo, B.; Silvestri, I.; Papini, N.; Anastasia, L.; Tettamanti, G,; Venerando, B. The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling β1 integrin internalization and recycling. J Bio. Chem. 2012, 287, 42835-42845.
20. Katopodis, N.; Hirshaut, Y.; Geller, N. L.; Stock, C. C. Lipid-associated sialic acid test for the detection of human cancer. Cancer Res. 1982, 42, 5270-5275.
21. Pinto, G.; Caira, S.; Mamone, G.; Ferranti, P.; Addeo, F,; Picariello, G. Fractionation of complex lipid mixtures by hydroxyapatite chromatography for lipidomic purposes. J Chromatog. A. 2014, 1360, 82-92.
22. Shivananda Nayak, B.; Bhaktha, G. Relationship between sialic acid and metabolic variables in Indian type 2 diabetic patients. Lipids Health Dis. 2005, 4, 15-25.
23. Prajna, K.; Kumar, A.; Rai, S.; Shetty, S. K.; Rai, T.; Shrinidhi, M. B.; Shashikala, M. D. Predictive Value of Serum Sialic Acid in Type-2 Diabetes Mellitus and Its Complication (Nephropathy). J. Clin. Diagnos. Res. 2013, 7, 2435-2440.
24. Divija, D. A., Rajeshwari, A., & Nusrath, A. Evaluation of Serum Sialic Acid and Microalbuminuria in Diabetic Nephropathy, Int'l. J. Recent Trends in Sci Tech. 2013, 8, 219-222.
25. Galadari, S.; Rahman, A.; Pallichankandy, S.; Galadari, A.; Thayyullathil, F. Role of ceramide in diabetes mellitus: evidence and mechanisms. Lipids Health Dis. 2013, 12, 98-114.
26. Liu, G.; Han, F.; Yang, Y.; Xie, Y.; Jiang, H.; Mao, Y.; Wang, H.; Wang, M.; Chen, R.; Yang, J.; Chen, J. Evaluation of sphingolipid metabolism in renal cortex of rats with streptozotocin-induced diabetes and the effectsof rapamycin. Nephrol. Dial. Trans. 2011, 26, 1493-1502.
27. Itoh, Y.; Yano, T.; Sendo, T.; Sueyasu, M.; Hirano, K.; Kanaide, H.; Oishi R. Involvement of de novo ceramide synthesis in radiocontrast-induced renal tubular cell injury. Kidney Int. 2006, 69, 288-297.
28. Basnakian, A.G.; Ueda, N.; Hong, X.; Galitovsky, V.E.; Yin, X.; Shah, S.V. Ceramide synthase is essential for endonuclease-mediated death of renal tubular epithelial cells induced by hypoxia-reoxygenation. Am. J. Physiol. Renal. Physiol. 2005, 288, F308-F314.
29. Merscher, S., Fornoni, A. Podocyte pathology and nephropathy-sphingolipids in glomerular diseases. Frontiers Endocrinol. 2014, 5, 127-140.
30. Caruntu, C.; Negrei C.; Boda D.; Constantin, C.; Caruntu, A.; Neagu, M. Biotechnological advances for diagnosis of peripheral diabetic neuropathy. Roum Biotech. Lett. 2014, 19, 9846-9858.
31. Ghafoor, F.; Muhammad Aasim, M. Comparison of in-house developed elisa with hplc for measurement of HBA1c. J. Immunoassay Immunochem. 2013, 34, 305-312.